<SEC-DOCUMENT>0001558370-24-006141.txt : 20240429
<SEC-HEADER>0001558370-24-006141.hdr.sgml : 20240429
<ACCEPTANCE-DATETIME>20240429170031
ACCESSION NUMBER:		0001558370-24-006141
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240429
DATE AS OF CHANGE:		20240429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		24892285

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>cycc-20231231x10ka.htm
<DESCRIPTION>10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 4/29/2024 5:11:53 PM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: a5dc1f8a-5b78-4365-a876-0607ba2c01f3 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cycc="http://www.cyclacel.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityCentralIndexKey" id="Tc_lMIyVl6BG0q2VomkBhG4hw_1_1">0001130166</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:AmendmentFlag" id="Tc_jv8TfxMpqESAD4jru3MGRA_2_1">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentFiscalYearFocus" id="Tc_bHFCYAa_JE6WBTF3_6L-Yw_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentFiscalPeriodFocus" id="Tc_UbZuhwxaEk6hITU-VSyyYQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityRegistrantName" id="Hidden_tL2oQmtRC0mZLK9vIiSoIw">Cyclacel Pharmaceuticals, Inc.</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cycc-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_roDKPv3T-UabBA0YR-ktcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_26_2024_7FFeAjS8YUSrkLR0vOFgEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_NymzZFCcf0qNgu-5yAvKpw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_j20pSvIDfESVrpa1xIGz0g"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_d5459d77_9bb2_49a3_9b90_f9efb5ae440f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentType" id="Narr_nPfhrnOirEiN-mW6kU1qeg"><b style="font-weight:bold;">10-K/A</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Amendment No.1)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><a id="_8bd9d33e_a725_4602_8df2_151d3668ca1c"></a><a id="Tc_bqCiu7ipWUqRi3iihOfGXg_0_1"></a><a id="Tc_dCUpfjm7Y0yPyGOyd7jCOQ_1_0"></a><a id="Tc_0mrmeW48Ek2BI7vQOvewHw_2_0"></a><a id="Tc_YPjiovG6HUG9qnWkbbb0Pg_3_1"></a><a id="Tc_WF9uJDJb5USYE6U7ISPx0w_4_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentAnnualReport" id="Tc_uSuEt39qlkK1dVg4NrDXZQ_0_0"><b style="font-family:'Segoe UI Symbol';font-size:8.5pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentPeriodEndDate" id="Narr_NXeL6PNIxEaYa7EPJpw6AA"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:CurrentFiscalYearEndDate" id="Narr_1GB4L4XMN0-3j0ROLoOHFw"><b style="font-size:8.5pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8.5pt;font-weight:bold;">, 2023</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">OR</b></p></td></tr><tr><td style="vertical-align:bottom;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentTransitionReport" id="Tc_mNzQMMTaO0OlYD2qBrgSJA_3_0"><b style="font-family:'Segoe UI Symbol';font-size:8.5pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityFileNumber" id="Narr_EzI2m8XZk0WLFHL-rcqsRQ"><b style="font-size:8.5pt;font-weight:bold;">000-50626</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_tL2oQmtRC0mZLK9vIiSoIw;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&#160;INC</b></span><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_e10ebbef_adf9_4255_8d29_fdcaf1979daa"></a><a id="Tc_C2sf1iuzk0GUafeVCApg2Q_1_0"></a><a id="Tc_t_LekF-YaEqOftaIyrefrg_1_1"></a><a id="Tc_FJswYkdTV0eLgiQD--tYdw_3_0"></a><a id="Tc_LveEHXsDu0-jnh4mFo3ckA_4_0"></a><a id="Tc_Di0UgXKou0-7IGK2RMnlcg_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityIncorporationStateCountryCode" id="Tc_7g7lL6XWSEaM93HpA5HTAg_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityTaxIdentificationNumber" id="Tc_j8lW8u3e_kq-NlumLnlI2g_0_1"><b style="font-size:9pt;font-weight:bold;">91-1707622</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(State or Other Jurisdiction<br/>of Incorporation or Organization)</p></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer<br/>Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityAddressAddressLine1" id="Narr_Baj7iedXv0em3x_G8lxPkQ"><b style="font-size:9pt;font-weight:bold;">200 Connell Drive</b></ix:nonNumeric><span style="font-size:9pt;"><br/></span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityAddressAddressLine2" id="Narr_FBmak3gFSkapGzKoHm9o-w"><b style="font-size:9pt;font-weight:bold;">Suite&#160;1500</b></ix:nonNumeric><span style="font-size:9pt;"><br/></span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityAddressCityOrTown" id="Narr_lATntmXKA06o9ocOMDgcXg"><b style="font-size:9pt;font-weight:bold;">Berkeley Heights</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityAddressStateOrProvince" id="Narr_-sYTCU1SEkq0SKI9lMbTVA"><b style="font-size:9pt;font-weight:bold;">New Jersey</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityAddressPostalZipCode" id="Tc_5geIrcVdw0u52j2ngsm1AQ_3_1"><b style="font-size:9pt;font-weight:bold;">07922</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:CityAreaCode" id="Narr_EpcEy8l4sEKSzWQpqrFfYw"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:LocalPhoneNumber" id="Narr_UpSQ-Hd4uEStbI59eOTkug"><b style="font-size:9pt;font-weight:bold;">517-7330</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_7ad308dc_93cc_4a74_96cf_c11b93acf159"></a><a id="Tc__r_V71--9EKgK9P-xCyajg_1_0"></a><a id="Tc_3iqr4FRS2UemyMhMSPHGBQ_1_1"></a><a id="Tc_l5UP2JbN-kO0P2szsAFMeQ_1_2"></a><a id="Tc_C6ZVNyoC1ESx7FnpcvQMRg_2_2"></a><a id="Tc_IubnBimlVE-hP4MsGQKTZA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.11%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered </b></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w" name="dei:Security12bTitle" id="Tc_kWpNZl0800qJpt_5GLDP-w_2_0"><span style="font-size:9pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w" name="dei:TradingSymbol" id="Tc_tE-uBy4NVk6wXKp7pLNZcw_2_1"><span style="font-size:9pt;">CYCC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w" name="dei:SecurityExchangeName" id="Narr_Fa9BalgqSEKzQLu4si1Hbg"><span style="font-size:9pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:9pt;"> Capital Market</span></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg" name="dei:Security12bTitle" id="Tc_zMRMruZbmUep42Z3445zyw_3_0"><span style="font-size:9pt;">Preferred Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg" name="dei:TradingSymbol" id="Tc_OFpknJF5DUS74zixGxyKkA_3_1"><span style="font-size:9pt;">CYCCP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg" name="dei:SecurityExchangeName" id="Narr_cTKCoXO14ECJm3YmQ_cgbw"><span style="font-size:9pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:9pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;">None.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#8199;Yes&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#8199;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_siifVTM6n0yGVHq2P1CHpA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#8199;Yes&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#8199;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityVoluntaryFilers" id="Narr_difjs6xfZkKjKA3CYeQ3zQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#8199;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityCurrentReportingStatus" id="Narr_wuQ2NMPgJ02cM1PPd6J3Gw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#8199;No&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#8199;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityInteractiveDataCurrent" id="Narr_el0jlz1cbkyB48F7ScHXhg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#8199;No&#8201;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of&#8201;&#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><a id="_55959694_20c9_43a1_9829_31c2cc0e7959"></a><a id="Tc_hr_1pI3Afk2gahLb1JBMzg_0_0"></a><a id="Tc_x_L8rpjt5ESX-qTUWBL6DQ_0_1"></a><a id="Tc_IkDTNwiKEE-vIiWBVs4Qew_0_2"></a><a id="Tc_2LC8bm-PbEGfL92Y3mcbHQ_0_3"></a><a id="Tc_dhbmPOcCS0KPWspYgu6quA_1_1"></a><a id="Tc_nkOTNTH3zEGiKZOm90pgsw_1_2"></a><a id="Tc_S-yU9NWtzUuzV_VXJ5-PYg_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.09%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer </p></td><td style="vertical-align:top;width:33.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer </p></td><td style="vertical-align:top;width:12.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityFilerCategory" id="Tc_mzeqbf7HDEibs9MKWMGvIA_1_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:12.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntitySmallBusiness" id="Tc_KEZpTUDOz0mPJZ6WZR4jbw_1_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:33.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityEmergingGrowthCompany" id="Tc_joiHdWRUtkCQOsfa1Ubkxg_2_1"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:12.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report</span><span style="font-size:8pt;">. </span><span style="font-size:8pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:IcfrAuditorAttestationFlag" id="Narr_t0yZ_r-eP0W772If2r8lMQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_MhrZdgFvUESlsjZqkCn_7g"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;white-space:pre-wrap;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:EntityShellCompany" id="Narr_SxlZq6emHU-211D4DNE_Rw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">Yes</span><span style="display:inline-block;width:24.78pt;"></span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the registrant&#8217;s voting and non-voting common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate), as of June&#160;30, 2023 (based upon the closing sale price of&#8201;$8.84 of such shares on The NASDAQ Capital Market on June&#160;30, 2023), the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="Unit_Standard_USD_j20pSvIDfESVrpa1xIGz0g" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2023_roDKPv3T-UabBA0YR-ktcA" decimals="0" name="dei:EntityPublicFloat" id="Narr_3eWBnaqsEEKwVve-dsrOZQ">5,622,362</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 4pt 0pt;">As of April 26, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_NymzZFCcf0qNgu-5yAvKpw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_4_26_2024_7FFeAjS8YUSrkLR0vOFgEg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_7RRB6jcjEkiIsiuH5d8dDw">1,318,257</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;"> <span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_321a6bc1_4acf_4362_b65d_d20712825cc5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXPLANATORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A" name="dei:AmendmentDescription" id="Narr_U2Pj4vaIikOqHXNtpblHbg">This Amendment No. 1 on Form 10-K/A (this &#8220;Amendment&#8221;) amends the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 21, 2024 (the &#8220;Original 10-K&#8221;). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company&#8217;s filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In this Amendment, unless the context specifically indicates otherwise, &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Cyclacel&#8221; refer to Cyclacel Pharmaceuticals, Inc. and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_31058af0_d488_4d7d_b637_f4b3246c5cd9"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_89502"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item10"><span style="font-style:normal;font-weight:normal;">I</span><span style="font-style:normal;font-weight:normal;">tem 10.</span></a></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item10"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item11"><span style="font-style:normal;font-weight:normal;">I</span><span style="font-style:normal;font-weight:normal;">tem 11.</span></a></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item11"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item12"><span style="font-style:normal;font-weight:normal;">I</span><span style="font-style:normal;font-weight:normal;">tem 12.</span></a></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item12"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a> </p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item13"><span style="font-style:normal;font-weight:normal;">I</span><span style="font-style:normal;font-weight:normal;">tem 13.</span></a></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item13"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">20</p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item14"><span style="font-style:normal;font-weight:normal;">I</span><span style="font-style:normal;font-weight:normal;">tem 14.</span></a></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item14"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_593016"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:85.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_60220dec_3574_420d_bd48_751f586383b2"></a><a id="PARTIII_89502"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;</b><b style="font-weight:bold;">III</b></p><a id="item10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Item 10. Directors, Executive Officers and Corporate </b><b style="font-weight:bold;letter-spacing:-0.2pt;">Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">The Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our charter provides that our business is to be managed by or under the direction of our Board of Directors. Our Board of Directors is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term. Our Board of Directors currently consists of three classes, as set forth below. We also have two directors who are elected by holders of our 6% Convertible Exchangeable Preferred Stock (the &#8220;Preferred Stock&#8221;),</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Set forth below, as of December&#160;31, 2023, are the names of our directors, their ages, their offices in the Company, if any, their principal occupations or employment for at least the past five&#160;years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five years. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors&#8217; conclusion at the time of filing of this proxy statement that each person listed below should serve as a director is set forth below:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:24.83%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:67.7%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:24.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Name</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:3.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Age</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:67.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Position</b></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Spiro Rombotis</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">65</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">President and Chief Executive Officer; Class&#160;2 Director</span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Paul McBarron</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">63</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Executive Vice President&#8201;&#8212;&#8201;Finance, Chief Financial Officer, Chief Operating Officer and Secretary; Class&#160;3 Director Nominee</span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Christopher Henney</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">83</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Chairman; Class&#160;3 Director Nominee</span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Robert Spiegel</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">74</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Vice Chairman; Class&#160;3 Director Nominee</span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Samuel L. Barker</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">81</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class&#160;2 Director on behalf of our holders of Preferred Stock</span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Kenneth M. Ferguson</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">68</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class&#160;1 Director on behalf of our holders of Preferred Stock</span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Brian Schwartz</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">62</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class&#160;2 Director; Interim Chief Medical Officer </span></p></td></tr><tr><td style="vertical-align:top;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Karin L. Walker</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">60</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:67.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class&#160;1 Director</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Board Diversity Matrix</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.2pt;">(as of April&#160;23, 2024)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">This table provides information on the diversity of our current Board of Directors:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total Number of Directors</b></p></td><td style="vertical-align:bottom;width:2.08%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"/><td colspan="10" style="vertical-align:bottom;width:32.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">8</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.08%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Male</b></p></td><td style="vertical-align:bottom;width:1.32%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1.32%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Female</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Directors</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"/><td colspan="4" style="vertical-align:bottom;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"/><td colspan="4" style="vertical-align:bottom;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Part&#160;I: Gender Identity</b></p></td><td colspan="6" style="vertical-align:bottom;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"/><td colspan="6" style="vertical-align:bottom;width:16.83%;background:#cceeff;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Part&#160;II: Demographic Background</b></p></td><td colspan="6" style="vertical-align:bottom;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"/><td colspan="6" style="vertical-align:bottom;width:16.83%;background:#cceeff;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">White</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"/><td colspan="4" style="vertical-align:bottom;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"/><td colspan="4" style="vertical-align:bottom;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Did not Disclose Demographic Background</span></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"/><td colspan="10" style="vertical-align:bottom;width:32.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">1</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Class&#160;1 Director (Term to Expire in 2025)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Karin L. Walker</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Ms.&#160;Walker has served as a director of the Company since November&#160;2020 and has over 30&#160;years of extensive finance experience in biopharmaceuticals, including in public biotechnology companies and technology companies. Ms.&#160;Walker currently serves as the Chief Accounting Officer of Prothena Corporation plc, a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics focused on neurodegenerative and rare peripheral amyloid diseases, and has held this position since 2013. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc., a position she held from 2012 to 2013. From 2009 to 2012, Ms.&#160;Walker was Vice President, Finance and Corporate Controller at Amyris Inc. From 2006 to 2009, she was Vice President, Finance and Corporate Controller for CV Therapeutics, Inc. Ms.&#160;Walker also held senior financial leadership positions at Knight Ridder Digital, Accellion, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Niku Corporation, Financial Engines, Inc. and NeoMagic Corporation. Ms.&#160;Walker also served as a director and Audit Committee Chair for LifeSci Acquisition Corp. (a publicly-traded special purpose acquisition company) in 2020. Ms.&#160;Walker earned her B.S. in business from the California State Polytechnic University, San Luis Obispo, and is a certified public accountant (CPA). We believe that Ms.&#160;Walker&#8217;s qualifications to serve on the Board of Directors include experience in the biotechnology and pharmaceutical industry and her many&#160;years&#8217; experience in finance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Class&#160;2 Directors (Terms to expire in 2026)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Spiro Rombotis</span>.&#160;&#160;&#160;Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has over 38 years at three public biotechs and two pharmas. He participated in in-licensing, clinical development, regulatory approval, partnering and commercial launch of several drugs, mainly in inflammation and hematology/oncology, including Abelcet&#174;, Evacet/Myocet&#174;, ProHance&#174;, Remicade&#174;&#160;and Reopro&#174;. Major functional roles included international operations and business development as Vice President at Liposome (subsequently acquired by Elan) and previously Vice President in the pharmaceuticals division of Bristol-Myers Squibb. He began his career in the early &#8217;80s, after training at Novartis, as one of the first employees of Centocor (subsequently acquired by Johnson &amp; Johnson). He holds an MBA and MPH (Hospital &amp; Health Services Management) with honors, Kellogg School of Management, Northwestern University and a BA, Williams College (1981 James A. Garfield Scholar). He serves on the Board of Trustees of BioNJ, the NJ biotech association. We believe Mr. Rombotis&#8217; qualifications to serve on the Board of Directors include his role as President and Chief Executive Officer of our Company, his extensive knowledge and experience in the biotechnology and life sciences industry and his leadership, strategic guidance and operational vision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Brian Schwartz, M.D</span>.&#160;&#160;&#160;Dr.&#160;Schwartz has served as a director of the company since December&#160;2020 and as our interim Chief Medical Officer since January 2024. Dr.&#160;Schwartz has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries primarily in oncology, hematology, and rare diseases. From June&#160;2008 to 2020, he served as Senior Vice President, Head of Research &amp; Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7&#160;billion by Merck &amp; Co. in 2020. Prior to ArQule, Dr.&#160;Schwartz was Chief Medical Officer at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma. He is a current Board Member of Enlivex Pharmaceuticals and also served as a director of LifeSci Acquisition Corp., Mereo Biopharma and Infinity. In addition, he serves as an advisor and independent consultant for numerous biotech and investment companies. He received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior to his career in the biopharmaceutical industry. We believe Dr.&#160;Schwartz&#8217;s qualifications to serve on the Board of Directors include his extensive knowledge and experience in the biotechnology and life science industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Continuing Preferred Stock Class&#160;1 Director (Term to Expire in 2025)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dr.&#160;Kenneth M. Ferguson</span><i style="font-style:italic;letter-spacing:0.2pt;">.</i><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Dr.&#160;Ferguson has worked in the biopharmaceutical industry for 30&#160;years, and has led Research and Development operations in a number of publicly funded biotechnology companies. Dr.&#160;Ferguson is currently an operating partner at Accelerator Life Science Partners. He served at ICOS Corporation, at various times in its history, as President, Vice President of Therapeutic Development and Senior Director of Research. He was co-team leader of ICOS&#8217; joint venture with Eli Lilly and Company that resulted in the launch of Cialis</span><span style="letter-spacing:0.15pt;">&#174;</span><span style="letter-spacing:0.2pt;">/Adcirca</span><span style="letter-spacing:0.15pt;">&#174;</span><span style="letter-spacing:0.2pt;">&#160;for the treatment of erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension. Subsequently, Dr.&#160;Ferguson was Vice President of Development and Chief Development Officer at Omeros Corporation and was involved in the approval and the launch of its first product for use in cataract surgery. Dr.&#160;Ferguson has also served as President and CEO of privately held Imvaxyn Corporation, a company dedicated to the exploration of new vaccine technology and was Chief Scientific Officer of EMulate Therapeutics. Dr.&#160;Ferguson graduated in biological sciences from Cornell University, obtained his PhD in pharmacology from the University of Texas Health Sciences Center Dallas, and completed his postdoctoral studies at Cold Spring Harbor Laboratory in New York. We believe Dr.&#160;Ferguson&#8217;s qualifications to serve on the Board of Directors include his extensive knowledge and business experience in the biotechnology industry, including as an executive in public companies, where he developed specific expertise in research and development of pharmaceutical products.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Continuing Preferred Stock Class&#160;2 Director (Term to Expire in 2026)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Samuel L. Barker</span>.&#160;&#160;&#160;Dr.&#160;Barker has served as a director of the Company since September&#160;2014. In 2001, Dr.&#160;Barker co-founded Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies, where he was active until September&#160;2010, having served as its President and Chief Executive Officer from 2003 to 2004. Dr.&#160;Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as Executive Vice President, Worldwide Franchise Management and Strategy during 1998; President, United States Pharmaceuticals from 1992 to 1998; and President, Bristol-Myers Squibb Intercontinental Commercial Operations from 1989 to 1991. Prior to 1989, Dr.&#160;Barker held executive positions in research and development, manufacturing, business development and served as President of U.S. commercial operations at Squibb Pharmaceuticals. Dr.&#160;Barker has served as a director of Lexicon Pharmaceuticals, Inc. since 2001 and as Chairman from 2005 to 2012. Dr.&#160;Barker also served as a director of Cadence Pharmaceuticals, Inc. from 2006 to 2014 and AtheroGenics, Inc. from 2005 to 2009. Dr.&#160;Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University. We believe that Dr.&#160;Barker&#8217;s qualifications to serve on the Board of Directors include his extensive experience in senior leadership positions in the global pharmaceutical industry, where he developed specific expertise in the identification, development, commercialization and partnering of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Class&#160;3 Directors (Terms to Expire in 2027; if re-elected)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Christopher S. Henney, Ph.D. D.Sc</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Dr.&#160;Henney has served as a director of the Company since March&#160;2006. Dr.&#160;Henney became Chairman of the Board of Directors of the Company in October&#160;2020. Dr.&#160;Henney had served as a director of Xcyte Therapies Inc., acquired by the Company in 2006, since March&#160;2005, and continued on as Vice Chairman of the Company. Previously, Dr.&#160;Henney co-founded three major publicly held U.S. biotechnology companies, Immunex, ICOS and Dendreon, and held a seat on the board of directors and executive positions at each company. From 1995 to January&#160;2003, Dr.&#160;Henney was Chairman and Chief Executive Officer of Dendreon Corporation. During part of 2016, he was also interim President and Chief Executive Officer of Cascadian Therapeutics Inc. and a board member of Anthera Pharmaceuticals, Inc., both biotechnology companies. Dr.&#160;Henney was a director of Prothena Corporation plc from 2013 until May&#160;2022. Dr.&#160;Henney received a Ph.D. in experimental pathology from the University of Birmingham and a D.Sc. from the same university for contributions to the field of immunology. In 2012, Dr.&#160;Henney was inducted into the Biotechnology Hall of Fame. We believe Dr.&#160;Henney&#8217;s qualifications to serve on the Board of Directors include his extensive knowledge and business experience in the biotechnology industry, including a diversified background as an executive in public companies and as a board member of many public companies, giving him a breadth of knowledge and valuable understanding of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Paul McBarron</span>.&#160;&#160;&#160;Mr.&#160;McBarron has served as a director of the Company since March&#160;2006. Mr.&#160;McBarron joined Cyclacel in January&#160;2002 and has over 30&#160;years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst &amp; Young and served on the Scottish Lifesciences Association Board. We believe Mr.&#160;McBarron&#8217;s qualifications to serve on the Board of Directors include his role as Executive Vice President, Finance and Chief Operating Officer of our Company, his experience in the biotechnology and pharmaceutical industry and his expertise in financial areas and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Robert J. Spiegel, M.D</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Dr.&#160;Spiegel has served as a director of the Company since September&#160;2018. Dr.&#160;Spiegel has over 30&#160;years of extensive R&amp;D and operational experience in biopharmaceuticals, including large pharmaceutical and biotechnology companies, and academic startups as well as an advisor to venture capital and private equity funds. Dr.&#160;Spiegel has also served as a director of Athenex, Inc., a global biopharmaceutical company, since August&#160;2020, of Geron Corp., a late-stage clinical biopharmaceutical company, since May&#160;2010, and of Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, since December&#160;2017. Dr.&#160;Spiegel was an Assistant Professor and Director of the Developmental Therapeutics Program at New York University Medical Center and then spent 25&#160;years at Schering-Plough (subsequently acquired by Merck &amp; Co.), where he joined as </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">the first Director for Oncology Clinical Research. He subsequently held a series of senior executive positions, including Senior Vice President for Worldwide Clinical Research and Chief Medical Officer. During his time at Schering-Plough he led teams that took numerous drug candidates through clinical development and was involved with over 30 New Drug Application approvals by the U.S. FDA. For the last seven&#160;years, he has been a consultant to the biotech industry and has served on the Scientific Advisory Board and Board of Directors of multiple biotech companies. Dr.&#160;Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. He completed his specialty training at the National Cancer Institute, National Institute of Health (NIH). We believe Dr.&#160;Spiegel&#8217;s qualifications to serve on the Board of Directors include his extensive knowledge and business experience in the biotechnology industry, including a diversified background as an executive in public companies and as a board member of several public companies, giving him a breadth of knowledge and valuable understanding of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.2pt;">Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with the Company, either directly or indirectly. Based upon this review, our Board of Directors has determined that each of the following directors is an &#8220;independent director&#8221; as such term is defined by rules of The Nasdaq Stock Market, Inc., or Nasdaq:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Christopher S. Henney, Ph.D., D.Sc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Robert J. Spiegel, M.D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Samuel L. Barker, Ph.D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kenneth M. Ferguson, Ph.D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Karin L. Walker</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Board of Directors has established three standing committees: (1)&#160;the Compensation and Organization Development Committee, (2)&#160;the Audit Committee, and (3)&#160;the Nominating and Corporate Governance Committee. The Board of Directors has also determined that each member of these committees meets the independence requirements applicable to each such committee as prescribed by Nasdaq and the SEC. </span>Dr. Schwartz will not be considered an independent director while serving as interim Chief Medical Officer. Following his appointment on January 25, 2024, <span style="letter-spacing:0.2pt;">Dr Schwartz resigned</span> from the Nominating and Corporate Governance Committee.<span style="letter-spacing:0.2pt;"> In September&#160;2018, the Board of Directors also reconstituted the Science and Technology Committee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Committees of the Board of Directors and Meetings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Meeting Attendance</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;During fiscal 2023, there were 11 meetings of our Board of Directors, and the Compensation and Organization Development Committee, the Audit Committee, the Nominating and Corporate Governance Committee and the Science and Technology Committee met collectively a total of 15 times. No director attended fewer than 55% of the total number of meetings of the Board of Directors or of the committees of the Board of Directors on which they served during fiscal 2023. We have adopted a policy encouraging our directors to attend annual meetings of stockholders. Five of our then directors attended our annual stockholders&#8217; meeting held on June&#160;13, 2023. Each of the committees of the Board of Directors is described below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Audit Committee</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Our Audit Committee met six times during fiscal 2023. The Audit Committee during such period had four members: Karin L. Walker (Chair), Dr.&#160;Christopher Henney, Dr.&#160;Samuel L. Barker and Dr.&#160;Robert J. Spiegel. Karin L. Walker was appointed as Chairman of the Audit Committee on February&#160;18, 2021. All members of the Audit Committee satisfy the current independence standards promulgated by Nasdaq and the SEC, as such standards apply specifically to members of audit committees. The Board of Directors has determined that Karin L. Walker is an &#8220;audit committee financial expert,&#8221; as the SEC has defined that term in Item&#160;407 of Regulation&#160;S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Our Audit Committee&#8217;s role and responsibilities are set forth in the Audit Committee&#8217;s written charter and include the authority to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual financial statements, considers matters relating to accounting policy </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">and internal controls and reviews the scope of annual audits. For additional information, please see the report of the Audit Committee set forth elsewhere in this proxy statement. A copy of the Audit Committee&#8217;s written charter is publicly available on our website at&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">www.cyclacel.com</i><span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Compensation and Organization Development Committee</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Our Compensation and Organization Development Committee met three times during fiscal 2023. The Compensation and Organization Development Committee is composed entirely of directors who are not our current or former employees, all of whom qualify as independent under the definition promulgated by Nasdaq and the SEC. The Compensation and Organization Development Committee currently has three members: Dr.&#160;Samuel L. Barker (Chairman), Dr.&#160;Christopher S. Henney and Dr.&#160;Kenneth M. Ferguson. Our Compensation and Organization Development Committee&#8217;s role and responsibilities are set forth in its written charter and include reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of the Board of Directors are carried out and that such policies, practices and procedures contribute to our success. The Compensation and Organization Development Committee also administers our 2020 Inducement Equity Incentive Plan, our 2018 Equity Incentive Plan, our 2015 Equity Incentive Plan and our Amended and Restated 2006 Equity Incentive Plan, as amended. Our Compensation and Organization Development Committee is responsible for the determination of the compensation of our chief executive officer, and shall conduct its decision making process with respect to that issue without the chief executive officer present.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">A copy of the Compensation and Organization Development Committee&#8217;s written charter is publicly available on our website at www.cyclacel.com.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Nominating and Corporate Governance Committee</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Our Nominating and Corporate Governance Committee met </span><i style="font-style:italic;">[</i>once]<span style="letter-spacing:0.2pt;"> during fiscal 202</span><i style="font-style:italic;">3</i><span style="letter-spacing:0.2pt;">. The Nominating and Corporate Governance Committee consists of Dr.&#160;</span><span style="letter-spacing:0.2pt;white-space:pre-wrap;">Christopher S. Henney (Chairman),  Karin L. Walker and Dr.&#160;Robert J. Spiegel, all of whom qualify as independent under the definition promulgated by Nasdaq and the SEC. </span>Dr.&#160;Brian Schwartz resigned from the Nominating and Corporate Governance Committee when appointed interim Chief Medical Officer on January 25, 2024. <span style="letter-spacing:0.2pt;">The functions of the Nominating and Corporate Governance Committee are set forth in the Nominating and Corporate Governance Committee&#8217;s charter and include evaluating and making recommendations to the full Board of Directors as to the size and composition of the Board of Directors and its committees, evaluating and making recommendations as to potential candidates, and evaluating the performance of the Board of Directors. Generally, our Nominating and Corporate Governance Committee considers candidates recommended by stockholders as well as from other sources such as other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating and Corporate Governance Committee will evaluate a candidate&#8217;s qualifications in accordance with its guiding principles as set forth in the Nominating and Corporate Governance Committee&#8217;s written charter. Additionally, the Nominating Committee will consider issues of diversity among its members in identifying and considering nominees for director, and strive where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, ethnicity</span> and country of citizenship on our board of directors and its committees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">If a stockholder wishes to nominate a candidate for director who is not to be included in our proxy statement, it must follow the procedures described in our By-Laws and in &#8220;</span><i style="font-style:italic;letter-spacing:0.2pt;">Stockholder Proposals and Nominations for Director</i><span style="letter-spacing:0.2pt;">&#8221; at the end of this proxy statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, under our current corporate governance policies, the Nominating and Corporate Governance Committee may consider candidates recommended by stockholders as well as from other sources, such as other directors or officers, third party search firms or other appropriate sources. For all potential candidates, the Nominating and Corporate Governance Committee may consider all factors it deems relevant, such as a candidate&#8217;s personal integrity and sound judgment, business and professional skills and experience, independence, knowledge of the industry in which we operate, possible conflicts of interest, diversity, the extent to which the candidate would fill a present need on the Board of Directors and concern for the long-term interests of the stockholders. In general, persons recommended by stockholders will be considered on the same basis as candidates from other sources.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">A copy of the Nominating and Corporate Governance Committee&#8217;s written charter is publicly available on our website at&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">www.cyclacel.com</i><span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Science and Technology Committee</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;The Science and Technology Committee, which met 4 times during fiscal 2023, consists of Dr.&#160;Robert J. Spiegel (Chairman), Dr.&#160;Samuel L. Barker, Dr.&#160;Kenneth M. Ferguson and Dr.&#160;Brian Schwartz.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The responsibilities of the Science and Technology Committee are set forth in the Science and Technology Committee&#8217;s charter and include providing oversight on behalf of the Board of Directors of our overall strategic direction and investment in research and development (&#8220;R&amp;D&#8221;) and technological and scientific initiatives. The Science and Technology Committee also assists the Board of Directors and our management in evaluating risks and potential commercial value of technical profiles regarding our R&amp;D programs and technology, as they might impact our business performance, growth and competitive position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Christopher Henney serves as the Chairman of our Board of Directors and Mr.&#160;Rombotis serves as our President and Chief Executive Officer. Dr.&#160;Christopher Henney is an independent director under the definition promulgated by Nasdaq and the SEC, and we believe that it is preferable for one of our independent directors to serve as Chairman of the Board of Directors. We also believe that this structure is the most effective structure for us and our stockholders at this time because a separate chairman (i)&#160;can provide the Chief Executive Officer with guidance and feedback on his performance, (ii)&#160;provides a more effective channel for the Board of Directors to express views on management, and (iii)&#160;allows the Chairman to focus on stockholder interests and corporate governance while providing Mr.&#160;Rombotis with the ability to focus his attention on managing our day-to-day operations. As Dr.&#160;Henney has significant senior level pharmaceutical industry experience, he is particularly well-suited to serve as Chairman.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We recognize that different board leadership structures may be appropriate for companies in different situations. We will continue to re-examine our corporate governance policies and leadership structures on an ongoing basis to ensure that they continue to meet the Company&#8217;s needs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Role in Risk Oversight</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Management is responsible for managing the risks that we face. The Board of Directors is responsible for overseeing management&#8217;s approach to risk management that is designed to support the achievement of organizational objectives, including strategic objectives and risks associated with our clinical trials, to improve long-term organizational performance and enhance stockholder value. The involvement of the full Board of Directors in reviewing our strategic objectives and plans, including with respect to our clinical trials, is a key part of the Board of Directors&#8217; assessment of management&#8217;s approach and tolerance to risk. A fundamental part of risk management is not only understanding the risks a company faces and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for us. In setting our business strategy, our Board of Directors assesses the various risks being mitigated by management and determines what constitutes an appropriate level of risk for us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">While the Board of Directors has ultimate oversight responsibility for overseeing management&#8217;s risk management process, various committees of the Board of Directors assist it in fulfilling that responsibility. Notably, the Audit Committee assists the Board of Directors in its oversight of risk management in the areas of financial reporting, internal controls and compliance with legal and regulatory requirements, the Nominating and Corporate Governance Committee reviews legal and regulatory compliance risks and the Compensation and Organization Development Committee assists the Board of Directors in its oversight of the evaluation and management of risks related to our compensation policies and practices.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Policy Prohibiting Hedging</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our Insider Trading Policy provides that no employee, officer or director may acquire, sell or trade in any interest or position relating to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale &#8220;against the box&#8221;), or engage in hedging transactions (including &#8220;cashless collars&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Stockholder Communications to the Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Generally, stockholders who have questions or concerns should contact our Investor Relations department at (908) 517-7330 or e-mail at&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">ir@cyclacel.com</i><span style="letter-spacing:0.2pt;">. However, stockholders wishing to submit written communications directly to the Board of Directors should send their communications to our Secretary, Paul McBarron, Cyclacel Pharmaceuticals, Inc., 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922. All stockholder communications will be considered by the independent members of our Board of Directors. Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">junk mail and mass mailings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">resumes and other forms of job inquiries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">surveys; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">solicitations or advertisements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any independent director upon request.</span></p><a id="_cd1ab51e_822d_4a00_8018_7811d1ee6bd9"></a><a id="item11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 11. Executive </b><b style="font-weight:bold;">Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following table shows the compensation paid or accrued during the last two fiscal&#160;years ended December&#160;31, 2022 and 2023 to (1)&#160;our President and Chief Executive Officer, (2)&#160;our Executive Vice President, Finance, Chief Financial Officer and Chief Operating Officer, and (3)&#160;our former Senior Vice President and Chief Medical Officer.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name and Principal Position</p></td><td style="vertical-align:bottom;width:0.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:8.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year</p></td><td style="vertical-align:bottom;width:0.88%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:8.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salary<br/>($)</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:8.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bonus<br/>($)</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:8.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option<br/>Awards<br/>($)(1)</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All Other<br/>Compensation<br/>($)(2)</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:8.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total<br/>($)</p></td><td style="vertical-align:bottom;width:0.8%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Spiro Rombotis </p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">560,131</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48,581</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52,337</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">661,049</p></td><td style="vertical-align:bottom;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">546,470</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">169,406</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47,675</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">763,551</p></td><td style="vertical-align:bottom;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paul McBarron(3)</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">304,214</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31,003</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17,398</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">352,615</p></td><td style="vertical-align:bottom;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">279,568</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93,655</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21,452</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">394,675</p></td><td style="vertical-align:bottom;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#ffffff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mark Kirschbaum, MD </p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">396,760</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31,003</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52,855</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">480,618</p></td><td style="vertical-align:bottom;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Former Senior Vice President and Chief Medical Officer (4)</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">381,500</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">97,644</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44,699</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">523,843</p></td><td style="vertical-align:bottom;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These amounts represent the aggregate grant date fair value for option awards computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in our Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. No Options were granted during the year ended December 31, 2022 to Spiro Rombotis, Paul McBarron, or Mark Kirschbaum. Options were granted during the year ended December 31, 2023 to Spiro Rombotis, Paul McBarron, and Mark Kirschbaum in the amounts of 7,333 shares, 4,680 shares, and 4,680 shares, respectively.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of the following for all executive officers: Payments for private medical and health insurance, life insurance and permanent health insurance; and matching contributions made under the Company&#8217;s U.S. 401(k) Plan and U.K. Group Personal Pension Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr. McBarron&#8217;s compensation was translated from British pound sterling to the U.S. dollar using the exchange rates of 1.35104 as of December 31, 2022 and 1.24361 as of December 31, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Kirschbaum was terminated as Chief Medical Officer on January 25, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Narrative Disclosure to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Compensation and Organization Development Committee of our Board of Directors makes decisions regarding the compensation of our President and Chief Executive Officer. The Compensation and Organization Development Committee is composed entirely of independent directors and meets in executive sessions to discuss and formulate its recommendation for the Chief Executive Officer&#8217;s base salary and bonus. The Compensation and Organization Development Committee does not rely solely on any predetermined formula or a limited set of criteria in evaluating the Chief Executive Officer&#8217;s performance for the year but does consider the achievement of preset goals as part of its deliberations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The evaluation is based on the Chief Executive Officer&#8217;s success in achieving his performance goals, which include financial, strategic and leadership objectives. The Chief Executive Officer also provides the Compensation and Organization Development Committee with a self-review of his performance as part of the Company&#8217;s review process. The Compensation and Organization Development Committee also approves the annual compensation (including base salary, bonus, and stock-based compensation) for our other named executive officers based on:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">the executive&#8217;s scope of responsibilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">an informed market assessment of competitive practices for similar roles within peer group companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">evaluations of performance for the year, as assessed by the Chief Executive Officer, supported by the Company&#8217;s performance review process and the executive&#8217;s self-assessment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">recommendations by our Chief Executive Officer for each named executive officer with respect to base salary, cash bonus, and stock-based compensation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Compensation and Organization Development Committee is authorized to engage and retain independent consultants and other experts to assist in fulfilling its responsibilities, and the Committee engages periodically an external consultant to provide independent verification of market position and ensure the appropriateness of executive compensation. During the year ended December&#160;31, 2023, our Compensation and Organization Development Committee retained Radford, part of the Aon Rewards Solutions practice, or Radford, an independent, executive compensation consulting firm, to review and provide recommendations concerning our non-employee director and executive director compensation programs. Radford performed services solely on behalf of the Compensation and Organization Development Committee and has no relationship with the Company or management beyond the performance of such services (except that Aon plc provides directors &amp; officers insurance services to the Company). The Compensation and Organization Development Committee has assessed the independence of Radford pursuant to SEC rules and the corporate governance rules of The Nasdaq Stock Market and has concluded that no conflict of interest exists that would prevent Radford from independently representing the Compensation and Organization Development Committee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">During the most recent year ended December&#160;31, 2023, the Board of Directors and the Compensation and Organization Development Committee reviewed the annual compensation for our executive officers. The Compensation and Organization Development Committee determined to provide increases in base salary for 2023 to Spiro Rombotis, Paul McBarron and Mark Kirschbaum, raising annual salaries to $560,131, &#163;244,622 (or $304,214) and $396,760, respectively.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We granted 3,840, 2,080, and 2,080 restricted stock units to Spiro Rombotis, Paul McBarron and Mark Kirschbaum, respectively, during the year ended December&#160;31, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Spiro Rombotis, President and Chief Executive Officer</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;On April 28, 2023, we entered into a two-year employment agreement with Mr.&#160;Spiro Rombotis, effective January&#160;1, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Rombotis&#8217; current annual base salary is $560,131, which may be increased in the future in accordance with the terms of his employment agreement. Mr.&#160;Rombotis was paid an annual base salary of $560,131 for the year ending December&#160;31, 2023 and $546,470 for the year ending December&#160;31, 2022. Mr.&#160;Rombotis is also eligible for a yearly incentive cash bonus, based on a&#160;percentage of his then current base salary, if he meets certain corporate and individual performance criteria set by the Compensation and Organization Development Committee at the beginning of each year of employment. The agreement also provides for reimbursement of reasonable and necessary expenses incurred by Mr.&#160;Rombotis in connection with his performance of his services. Mr.&#160;Rombotis is also entitled to certain employment benefits in accordance with the Company&#8217;s benefit policies in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Mr.&#160;Rombotis also agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following termination of his employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For further information on terms regarding termination and change-in-control of the Company, see <i style="font-style:italic;">&#8220;Potential Payments upon Termination or Change-in-Control&#8221;</i> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Paul McBarron, Executive Vice President&#8201;&#8212;&#8201;Finance, Chief Financial Officer, Chief Operating Officer and Secretary.</i><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;On April 28, 2023, we entered into a two-year employment agreement with Mr.&#160;Paul McBarron, effective January&#160;1, 2023. Mr.&#160;McBarron&#8217;s current annual base salary is &#163;244,622, or $304,214, which may be increased in the future in accordance with the terms of his employment agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Mr.&#160;McBarron was paid an annual base salary of &#163;244,622, or $304,214 for the year ending December&#160;31, 2023 and &#163;226,133, or $279,568, for the year ending December&#160;31, 2022, respectively. Mr.&#160;McBarron is also eligible for a yearly incentive cash bonus based on a&#160;percentage of his then current base salary, if he meets certain corporate and individual performance criteria set by the Compensation and Organization Development Committee at the beginning of each year of employment. The agreement also provides for reimbursement of reasonable and necessary expenses incurred by Mr.&#160;McBarron in connection with the performance of his services. Mr.&#160;McBarron is also entitled to certain employment benefits in accordance with the Company&#8217;s benefit policies in effect from time to time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, Mr.&#160;McBarron also agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following termination of his employment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">For further information on terms regarding termination and change-in-control of the Company, see &#8220;Potential Payments upon Termination or Change-in-Control&#8221; below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Mark Kirschbaum, Former Senior Vice President and Chief Medical Officer.&#160;&#160;&#160;On October&#160;17, 2020, we entered into an employment agreement with Dr.&#160;Mark Kirschbaum, effective October&#160;23, 2020. We terminated Dr.&#160;Kirschbaum&#8217;s employment on January&#160;25, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">&#160;Prior to his termination, Dr.&#160;Kirschbaum&#8217; annual base salary was $396,760. Dr.&#160;Kirschbaum was paid an annual base salary of $396,760 for the year ending December&#160;31, 2023 and $381,500 for the year ending December&#160;31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, Dr.&#160;Kirschbaum also agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations for a period of one year following termination of his employment.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EQUITY COMPENSATION PLAN INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at 2023 Fiscal Year-End</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following table shows grants of stock options outstanding on the last day of the fiscal year ended December&#160;31, 2023, to each of the executive officers named in the Summary Compensation Table. As applicable, the figures described in this section have been adjusted to give effect to the reverse stock split completed on December 15, 2023.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Securities </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Underlying </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;width:2.42%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.81%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Securities </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Underlying </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercisable</b></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Price(1)&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:0.91%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Expiration </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:0.91%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Spiro Rombotis</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,096.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">02/18/2025</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">121</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,120.40</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/07/2025</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">522.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/29/2027</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">95</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">468.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">02/22/2028</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,693</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">213.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">01/04/2029</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11,666</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(6)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64.80</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/11/2030</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8,444</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(8)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,222</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">51.75</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/13/2031</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(9)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7,333</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8.70</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">06/27/2033</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paul McBarron</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">14</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,096</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">02/18/2025</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,120.40</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/07/2025</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">522.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/29/2027</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">468.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">02/22/2028</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">900</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">213.00</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">01/04/2029</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8,000</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(6)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64.80</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/11/2030</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,444</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(8)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,222</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">51.75</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/13/2031</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(9)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,680</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8.70</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">06/27/2033</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mark Kirschbaum (10)</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8,000</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56.55</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10/23/2030</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,444</p></td><td style="vertical-align:bottom;width:2.42%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(8)</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,222</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">51.75</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/13/2031</p></td><td style="vertical-align:bottom;width:0.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(9)</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,680</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8.70</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">06/27/2033</p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The option exercise price is the closing price of our Common Stock on The Nasdaq Capital Market on the date the option was granted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on February&#160;18, 2015, and vest ratably on a monthly basis over 36 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on December&#160;7, 2015, and vest ratably on a monthly basis over 36 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain performance criteria were deemed to have been met in 2018 and 2019, and as such, performance-based options granted in 2017 and 2018 vested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on January&#160;4, 2019 and included part of the 2018 bonus award, and vest ratably on a monthly basis over 36 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on December&#160;11, 2020, and vest ratably on a monthly basis over 36 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on October&#160;23, 2020 and vest over 36 months as to one third (1/3) of the shares on the first anniversary of the Grant Date and as to one thirty-sixth (1/36) of the total number shares monthly thereafter.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on December&#160;13, 2021, and vest ratably on a monthly basis over 36 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options were granted on June&#160;27, 2023, and vest on achievement of certain performance criteria.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We terminated Dr.&#160;Kirschbaum&#8217;s employment on January&#160;25, 2024. These options have ceased vesting as of January&#160;25, 2024, and have not been exercised as of February&#160;6, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Potential Payments Upon Termination or Change-in-Control</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">We have entered into agreements that require us to make payments and/or provide benefits to certain of our executive officers in the event of a termination of employment or change-in-control. Our 2006 Equity Incentive Plan, or 2006 Plan, our 2015 Equity Incentive Plan, or 2015 Plan, our 2018 Equity Incentive Plan, or 2018 Plan, and our 2020 Inducement Equity Incentive Plan, or 2020 Plan (and collectively with the 2006 Plan, 2015 Plan, and 2018 Plan the &#8220;Plans&#8221;) provide for payments to named executive officers in connection with a termination or a change-in-control of the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following summarizes the potential payments to certain of our executive officers with whom we have entered into an employment agreement that includes a payment upon termination and/or a change-in-control, as further described below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Spiro Rombotis, President and Chief Executive Officer</i><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Mr.&#160;Rombotis&#8217;s employment agreement provides for certain severance arrangements. In the event that Mr.&#160;Rombotis&#8217;s employment is terminated &#8220;without cause,&#8221; other than termination in connection with a &#8220;change of control&#8221; &#8203;(each as defined in the employment agreement), we will be required to pay Mr.&#160;Rombotis (i)&#160;all accrued but unpaid compensation up to the time of such termination; (ii)&#160;for a period of twelve&#160;months following such termination, severance payments in the form of his base salary as in effect immediately prior to such termination, or Severance Payments, including form of continuation coverage of his medical care and life insurance on the same terms as applicable to other executive employees, unless Mr.&#160;Rombotis obtains substitute coverage; and (iii)&#160;a period of six&#160;months in which to exercise all vested options held by Mr.&#160;Rombotis. In the event that Mr.&#160;Rombotis&#8217;s employment is terminated within six&#160;months following a &#8220;change-in-control&#8221; event, Mr.&#160;Rombotis will be entitled to (i)&#160;all accrued but unpaid compensation up to the time of such termination; (ii)&#160;Severance Payments for a period of 24&#160;months; (iii)&#160;out-of-pocket expenses reasonably incurred by Mr.&#160;Rombotis in connection with his and his family&#8217;s relocation to London; and (iv)&#160;eighteen&#160;months&#8217; accelerated vesting of any options held by him. In the event of termination due to his death or disability, we will pay Mr.&#160;Rombotis (or his estate, as the case may be) (i)&#160;all accrued but unpaid compensation up to the time of such termination and (ii)&#160;Severance Payments for a period of twelve&#160;months. He (or his estate, as the case may be) would also be entitled to a period of twelve&#160;months in which all of his vested options can be exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Paul McBarron, Executive Vice President&#8201;&#8212;&#8201;Finance, Chief Financial Officer, Chief Operating Officer and Secretary.</i><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Mr.&#160;McBarron&#8217;s employment agreement provides for certain severance arrangements. In the event that Mr.&#160;McBarron&#8217;s employment is terminated &#8220;without cause,&#8221; other than termination in connection with a &#8220;change of control&#8221; &#8203;(each as defined in his employment agreement), we will be required to pay Mr.&#160;McBarron (i)&#160;all accrued but unpaid compensation up to the time of such termination; (ii)&#160;Severance Payments for a period of twelve&#160;months following such termination; and (iii)&#160;a period of six&#160;months in which to exercise all vested options held by Mr.&#160;McBarron. In the event that Mr.&#160;McBarron&#8217;s employment is terminated within six&#160;months following a &#8220;change-in-control&#8221; event, Mr.&#160;McBarron will be entitled (i)&#160;all accrued but unpaid compensation up to the time of such termination; (ii)&#160;Severance Payments for a period of twelve&#160;months; and (iii)&#160;eighteen&#160;months&#8217; accelerated vesting of any options held by him. In the event of termination due to his death or disability, we will pay Mr.&#160;McBarron (or his estate, as the case may be) all accrued but unpaid compensation up to the time of such termination and Severance Payments for a period of twelve&#160;months. He (or his estate, as the case may be) would also be entitled to a period of twelve&#160;months in which all of his vested options can be exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Potential payments to each named executive officer under our Plans in connection with a termination or a change-in-control of the Company</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following summarizes the potential payments to each named executive officer under the Plans in connection with a termination or a change-in-control of the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0.2pt;">Termination For Cause</b><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;If an award recipient&#8217;s service relationship with the Company terminates for &#8220;cause&#8221; (as defined in the Plans), then any unexercised award shall terminate immediately upon his or her termination of service.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0.2pt;">Termination Without Cause</b><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;If an award recipient&#8217;s service relationship with the Company terminates for any reason other than for &#8220;cause&#8221; &#8203;(excluding death or disability), then the recipient generally may exercise the award, to the extent vested, within 30&#160;days (in our 2006 Plan) or three&#160;months (in our 2015 Plan, 2018 Plan, and 2020 Plan), of such termination to the extent that the award is vested on the date of termination (but in no event later than the expiration of the term of the award as set forth in the award agreement). If the recipient dies within three&#160;months following such a termination, the award generally may be exercised, to the extent vested, within 180&#160;days&#8217; or one year (as per the 2006 Plan, 2015 Plan, 2018 Plan, and 2020 Plan, respectively) of the recipient&#8217;s death. If an award recipient&#8217;s service relationship with the Company terminates due to his or her death, the award recipient&#8217;s personal representative, estate, or the person who acquires the right to exercise the award by bequest or inheritance, as the case may be, generally may exercise the award, to the extent the award was vested on the date of termination, within one year from the date of the recipient&#8217;s death. Pursuant to the 2006 Plan, if an award recipient&#8217;s service relationship with the Company terminates due to his or her disability, the recipient, the recipient&#8217;s personal representative, estate, or the person who acquires the right to exercise the award by bequest or inheritance, as the case may be, generally may exercise the award, to the extent exercisable on the date of termination, within one year from the date of the recipient&#8217;s termination, or if the recipient dies during such one-year period, within the later of one year from the date of the recipient&#8217;s termination and 180&#160;days from the recipient&#8217;s death. In no event may an award be exercised later than the expiration of the term of the award as set forth in the award agreement. Pursuant to the 2015 Plan, 2018 Plan, and 2020 Plan, with regard to options outstanding on the date of an individual&#8217;s termination due to disability, he or she may exercise any option to the extent that the option is exercisable but has not been exercised on the date of termination. Such an individual is also entitled to any additional vesting rights that would have accrued on the next vesting date had he or she not become disabled. Exercise may only occur during the one-year period after the date of termination. With regard to stock grants and stock-based awards outstanding on the date of an individual&#8217;s termination due to disability, to the extent the forfeiture provisions or the Company&#8217;s rights of repurchase have not lapsed, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, they shall lapse to the extent of a pro&#160;rata portion of the shares subject to such stock grant or stock-based award through the date of disability as would have lapsed had the individual not become disabled.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0.2pt;">Change-in-Control</b><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Pursuant to the terms of the Plans, in the event of a change-in-control (as defined in the Plans), all outstanding awards granted under the Plans will be either:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumed by the successor corporation or a parent or subsidiary of the successor corporation; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substituted with an equivalent award by the successor corporation or a parent or subsidiary of the successor corporation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, in the event that the successor corporation refuses to assume or substitute an award:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">awards consisting of options, stock appreciation rights and rights to purchase restricted stock will become fully vested and immediately exercisable, including awards that would not otherwise have become vested or exercisable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all other awards will become fully earned and eligible to receive a payout.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">For the purposes of the Plans, a participant&#8217;s award will be considered assumed if, following the change-in-control, the assumed award confers, for each share of the Company&#8217;s Common Stock subject to the award immediately prior to the change-in-control, the right to receive the consideration (whether stock, cash, or other securities or property) received in the change-in-control for each share of Common Stock held on the effective date of the transaction; provided, however, that if the consideration received in the change-in-control is not solely common stock of the successor corporation or its parent, the committee administering the plan may, with the consent of the successor corporation, provide for the consideration per share to be received upon the exercise of the award, to be solely common stock of the successor corporation or its parent equal in fair market value to the per share consideration received by holders of the Company&#8217;s Common Stock in the change-in-control.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Plans, a change-in-control is the occurrence of one of the following events:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person, partnership, joint venture, corporation or other entity, or two or more of any of the foregoing acting as a group (or any &#8220;person&#8221; within the meaning of Sections&#160;13(d)(3) and 14(d) of the Exchange Act), other than the Company, a Subsidiary, or an employee benefit plan (or related trust) of the Company or a Subsidiary, become(s) the &#8220;beneficial owner&#8221; &#8203;(as defined in Rule&#160;13d-3 under the Exchange Act) of 30% or more of the then-outstanding voting stock of the Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">during any period of two consecutive&#160;years, individuals who at the beginning of such period constitute the Board of Directors (together with any new director whose election by the Board of Directors or whose nomination for election by the Company&#8217;s stockholders, was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the directors then in office;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all or substantially all of the business of the Company is disposed of pursuant to a merger, consolidation or other transaction in which the Company is not the surviving corporation or the Company combines with another Company and is the surviving corporation (unless the stockholders of the Company immediately following such merger, consolidation, combination, or other transaction beneficially own, directly or indirectly, more than 50% of the aggregate voting stock or other ownership interests of (x)&#160;the entity or entities, if any, that succeed to the business of the Company or (y)&#160;the combined company);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as a consequence of which the Board of Directors in office immediately prior to such transaction or event constitutes less than a majority of the Board of Directors thereafter; or the stockholders of the Company approve a sale of all or substantially all of the assets of the Company or a liquidation or dissolution of the Company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following table shows the total compensation paid or accrued during the fiscal year ended December&#160;31, 2023 to each of our non-employee directors. Directors who are employed by us are not compensated for their service on our Board of Directors. As applicable, the figures described in this section have been adjusted to give effect to the reverse stock split completed on December 15, 2023.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees Earned or Paid in Cash ($)</b></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Awards </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)(1)(2)</b></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Awards </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)(1)(3)</b></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:0.97%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Christopher S. Henney, Ph.D. D.Sc</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">136,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Spiegel, M.D.</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">115,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Samuel L. Barker, Ph.D.</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">97,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kenneth M. Ferguson, Ph.D.</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">54,000</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85,491</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian Schwartz, M.D.</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">53,000</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84,491</p></td><td style="vertical-align:bottom;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Karin L. Walker</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64,000</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18,991</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,500</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">95,491</p></td><td style="vertical-align:bottom;width:0.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These amounts represent the aggregate grant date fair value of options and restricted stock&#160;units granted to each director during the year ended December&#160;31, 2023 computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 11 to our financial statements included on our Form 10-K for the fiscal year ended December&#160;31, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fair value of the options granted on June&#160;30, 2023 was $6.71 per share. Each non-employee director held an aggregate of 2,829 stock options as of December&#160;31, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fair value of RSUs granted on June&#160;30, 2023 was $8.84 per share. Each non-employee director held an aggregate of 1,415 RSUs as of December&#160;31, 2023.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Compensation Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Under the terms of our Director Compensation Program, the non-employee members of our Board of Directors are paid a fixed annual fee, payable on a quarterly basis, in arrears, on the first day of each quarter, as follows:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:88.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85,000</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice Chairman of the Board</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65,000</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Non-Management Board Members</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">45,000</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Chair of each of the various committees of the Board of Directors will also receive the following fixed annual fee, payable on a quarterly basis, in arrears, on the first day of each quarter, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:88.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15,000</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and Organization Development</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10,000</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nominating and Corporate Governance</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8,000</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:88.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Science and Technology</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8,000</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The non-Chair members of each of the various committees of the Board of Directors will also receive the following fixed annual member fee, payable on a quarterly basis, in arrears, on the first day of each quarter, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:89.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:89.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7,500</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:89.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and Organization Development</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,000</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:89.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nominating and Corporate Governance</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,000</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:89.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Science and Technology</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,000</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8203;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In addition, the non-employee members of our Board of Directors are entitled to receive stock options and / or restricted stock options (RSUs) on their initial appointment to the Board and on an annual basis on the date of the Company&#8217;s annual meeting, such options and RSUs to vest fully on the first anniversary of the date of the grant. The non-employee directors are also reimbursed for customary business expenses in connection with attending Board of Directors and committee meetings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><a id="_765efe6e_7950_411d_80b0_04ba3c4e9222"></a><a id="item12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Item&#160;12.&#160;Security Ownership of Certain Beneficial Owners and </b><b style="font-weight:bold;letter-spacing:-0.2pt;">Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following table sets forth certain information with respect to the beneficial ownership of our Common Stock and our 6% Convertible Exchangeable Preferred Stock (the &#8220;Preferred Stock&#8221;) as of April 23, 2024 for (a) each of our named executive officers, (b)&#160;each of our directors and director nominees, (c)&#160;all of our current directors and executive officers as a group, and (d)&#160;each stockholder known by us to own beneficially more than 5% of our Common Stock or Preferred Stock, relying solely upon the amounts and&#160;percentages disclosed in their public filings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of Common Stock that may be acquired by an individual or group within 60&#160;days of April 23, 2024 pursuant to the exercise of options or warrants to be outstanding for the purpose of computing the&#160;percentage ownership of such individual or group but do not deem them to be outstanding for the purpose of computing the&#160;percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of stock shown to be beneficially owned by them based on information provided to us by these stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Percentage of ownership of Common Stock is based on 1,318,257 shares of Common Stock outstanding as of </span>April 23,<span style="letter-spacing:0.2pt;"> </span>2024<span style="letter-spacing:0.2pt;">. Percentage of ownership of Preferred Stock is based on 335,273 shares of Preferred Stock outstanding as of </span>April 23,<span style="letter-spacing:0.2pt;"> </span>2024<span style="letter-spacing:0.2pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The address for each of the directors, director nominees and named executive officers is c/o&#160;Cyclacel Pharmaceuticals, Inc., 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922. Addresses of other beneficial owners are noted in the table.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:37.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Name of Beneficial Owners</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Shares of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Common Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Beneficially</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Owned</b></p></td><td style="vertical-align:bottom;width:0.43%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Percentage of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Common Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Owned</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Shares of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Preferred Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Beneficially</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Owned</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.44%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Percentage of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Preferred Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Owned</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Samuel L. Barker</span></p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,155</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Kenneth M. Ferguson</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,636</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Christopher Henney</span></p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,089</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Paul McBarron</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16,611</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.26%</p></td><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Spiro Rombotis</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30,658</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2.33%</p></td><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,600</p></td><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Robert Spiegel</span></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,073</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Dr.&#160;Brian Schwartz</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25,028</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.90%</p></td><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Karin Walker</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,194</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Executive officers and directors as a group (8&#160;persons)</span><span style="font-family:'Tahoma';letter-spacing:0.15pt;">&#65279;</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91,444</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.94%</p></td><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,600</p></td><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">5% or more stockholders</i></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#8203;</i></p></td><td colspan="6" style="vertical-align:bottom;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#8203;</i></p></td><td colspan="6" style="vertical-align:bottom;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#8203;</i></p></td><td colspan="6" style="vertical-align:bottom;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#8203;</i></p></td><td colspan="6" style="vertical-align:bottom;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#8203;</i></p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Entities affiliated with Lind Global Fund II LP</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102,250</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7.76%</p></td><td style="vertical-align:bottom;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:37.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Entities affiliated with Altium Growth Fund, LP</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82,032</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.22%</p></td><td style="vertical-align:bottom;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">*</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">Represents beneficial ownership of less than 1% of the outstanding shares of our Common Stock or of our Preferred Stock.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">Includes options to purchase 175 shares of Common Stock that are exercisable within 60&#160;days of April 23, 2024 and 527 Restricted Stock Units that will vest within 60&#160;days of April 23, 2024.</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">Includes options to purchase 370 shares of Common Stock that are exercisable within 60&#160;days of April 23, 2024</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">Includes options to purchase 704 shares of Common Stock that are exercisable within 60&#160;days of April 23, 2024. Does not include 46 shares of Common Stock beneficially owned by Kalliopi Rombotis, Mr.&#160;Rombotis&#8217; mother. Mr.&#160;Rombotis disclaims beneficial ownership of the foregoing shares.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">Includes options to purchase 4,167 shares of Common Stock that are exercisable within 60&#160;days of April 23, 2024 and 4,167 Restricted Stock Units that will vest within 60&#160;days of April 23, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">Includes options to purchase 9 shares of Common Stock that are exercisable within 60&#160;days of April&#160;23, 2024.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">See footnotes 1 through and including 5.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(7)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based solely on Schedule 13G/A filed with the SEC on January&#160;4, 2024 by Lind Global Fund II, LP. Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP. Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">(8)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based solely on Schedule 13G/A filed with the SEC on January&#160;10, 2024 by Altium Growth Fund, LP. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by the Altium Growth Fund, LP (the &#8220;Fund&#8221;). Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities, owned by the Fund.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Equity Compensation Plan&#160;Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following table provides certain aggregate information with respect to all of our equity compensation plans in effect as of December&#160;31, 2023. As applicable, the figures described in this section have been adjusted to give effect to the reverse stock split completed on December 15, 2023.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:5.91%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:5.96%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:60.12%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(a)</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(b)</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(c)</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Plan&#160;Category</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Securities to be</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">issued upon</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">exercise of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">outstanding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">options,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">warrants and</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">rights</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Weighted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">exercise price</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">of outstanding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">options,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">warrants,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">and rights</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:0.62%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">Securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">remaining</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">available for</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">future issuance</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">under equity</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">compensation</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">plans (excluding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">reflected in</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;letter-spacing:-0.15pt;">column (a))</b></p></td><td style="vertical-align:bottom;width:0.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total equity compensation plans approved by security holders</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">137,446</p></td><td style="vertical-align:bottom;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59.11</p></td><td style="vertical-align:bottom;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22,466</p></td><td style="vertical-align:bottom;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:60.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Equity compensation plans not approved by security holders</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8,000</p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56.55</p></td><td style="vertical-align:bottom;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,333</p></td><td style="vertical-align:bottom;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Consists of our 2018 Plan, our 2015 Plan, and our 2006 Plan. The Plans provide for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock&#160;units and performance&#160;units. There were no shares available for issuance, as of the date hereof, under the 2006 Plan or the 2015 Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Consists of our 2020 Plan. The 2020 Plan provides for the grant of nonqualified stock options, stock appreciation rights, restricted stock, restricted stock&#160;units and performance&#160;units.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd0f331a_7525_450d_a565_e052f3482dc3"></a><a id="item13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Item&#160;13.&#160;&#160;&#160;Certain Relationships and Related </b><b style="font-weight:bold;letter-spacing:-0.2pt;">Transactions, and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our Audit Committee reviews and approves in advance all related-party transactions. Except as described below, there have been no transactions during our last two fiscal&#160;years with our directors and officers and beneficial owners of more than 5% of our voting securities and their affiliates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 21, 2023, in an insider private placement, we entered into an Insider Securities Purchase Agreement pursuant to which we agreed to sell in a private placement (i) 6,070 shares of common stock and warrants to purchase 6,070 shares of common stock, on the same terms as the unregistered warrants issued to certain institutional investors (the &#8220;Purchasers&#8221; and such warrants, the &#8220;Private Warrants&#8221;), to Spiro Rombotis, our Chief Executive Officer, and (ii) 1,886 shares of common stock and warrants to purchase 1,886 shares of common stock on the same terms as the Private Warrants issued to the Purchasers in the Offerings to Paul McBarron, our Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer. Each such share of common stock and accompanying warrant was sold at a purchase price of $3.315, which was the same purchase price for the shares of common stock sold in a concurrent registered direct offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with the Company, either directly or indirectly. Based upon this review, our Board of Directors has determined that each of the following directors is an &#8220;independent director&#8221; as such term is defined by rules of The Nasdaq Stock Market, Inc., or Nasdaq:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Christopher S. Henney, Ph.D., D.Sc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Robert J. Spiegel, M.D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Samuel L. Barker, Ph.D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kenneth M. Ferguson, Ph.D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Karin L. Walker</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Board of Directors has established three standing committees: (1)&#160;the Compensation and Organization Development Committee, (2)&#160;the Audit Committee, and (3)&#160;the Nominating and Corporate Governance Committee. The Board of Directors has also determined that each member of these committees meets the independence requirements applicable to each such committee as prescribed by Nasdaq and the SEC. </span>Dr. Schwartz will not be considered an independent director while serving as interim Chief Medical Officer. Following his appointment on January 25, 2024, <span style="letter-spacing:0.2pt;">Dr Schwartz resigned</span> from the Nominating and Corporate Governance Committee.<span style="letter-spacing:0.2pt;"> In September&#160;2018, the Board of Directors also reconstituted the Science and Technology Committee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><a id="_dac31f02_71f3_4a7f_8c5f_48faec9354ba"></a><a id="item14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Item&#160;14.&#160;&#160;&#160;Principal Accountant </b><b style="font-weight:bold;letter-spacing:-0.2pt;">Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Audit Committee has appointed RSM US LLP, or RSM, as our independent registered public accounting firm, to audit our consolidated financial statements for the fiscal year ended December&#160;31, 2024. The Board of Directors proposes that our holders of Common Stock ratify this appointment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The following table presents fees for professional audit services rendered by RSM for the audit of Cyclacel&#8217;s annual financial statements for the&#160;years ended December&#160;31, 2022 and 2023, and fees billed for other services rendered by them during those periods.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.28%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:1.39%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">2022</b></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">2023</b></p></td><td style="vertical-align:bottom;width:0.07%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Audit fees</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">331,916</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">335,430</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Tax fees</span><sup style="font-size:7.5pt;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:1.39%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27,300</p></td><td style="vertical-align:bottom;width:0.07%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31,164</p></td><td style="vertical-align:bottom;width:0.07%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr><tr><td style="vertical-align:bottom;width:74.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total</span></p></td><td style="vertical-align:bottom;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">359,216</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">366,594</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8203;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Audit fees represent fees for the audit of the Company&#8217;s annual consolidated financial statements, review of the Company&#8217;s interim financial statements included in quarterly reports on Form 10-Q, services that an independent auditor would customarily provide in connection with subsidiary audits, other regulatory filings and similar engagements for each fiscal year shown, such as attest services, comfort letters, consents and assistance with review of reports filed with the SEC.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Tax fees represent tax compliance and return preparation and tax planning and advice.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-audit Services of Independent Auditors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation, and overseeing the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve all audit and permissible non-audit services provided by our independent registered public accounting firm.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Prior to engagement of the independent auditor for the next year&#8217;s audit, management will submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">1.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Audit</span><span style="letter-spacing:0.2pt;">&#160;services include audit work performed in the preparation of financial statements, as well as work that generally only the independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits and attest services and consultation regarding financial accounting and/or reporting standards.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">2.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Audit-Related</span><span style="letter-spacing:0.2pt;">&#160;services are for assurance and related services that are traditionally performed by the independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits and special procedures required to meet certain regulatory requirements.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">3.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Tax</span><span style="letter-spacing:0.2pt;">&#160;services include all services performed by the independent registered public accounting firm&#8217;s tax personnel except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning and tax advice.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="letter-spacing:0.2pt;">4.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Other Fees</span><span style="letter-spacing:0.2pt;">&#160;are those associated with services not captured in the other categories. The Company generally does not request such services from our independent registered public accounting firm.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Prior to engagement, the Audit Committee pre-approves these services by category of service. The fees are budgeted and the Audit Committee requires our independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="letter-spacing:0.2pt;">During the year, circumstances may arise when it may become necessary to engage our independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Audit Committee requires specific pre-approval before engaging the independent registered public accounting firm.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">The Audit Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">In the event the stockholders do not ratify the appointment of RSM as our independent registered public accounting firm, the Audit Committee will reconsider its appointment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_56e36563_0940_4470_9e55_3017637ba0f4"></a><a id="PARTIV_593016"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 5.85pt;"><b style="font-weight:bold;">PART&#160;IV</b></p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;15.&#160;&#160;&#160;Exhibits and Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following documents are being filed as part of this report:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No financial statements are filed with this Amendment No.1 to our Annual Report Form 10-K. See Index to Consolidated Financial Statements at Item 8 of the Original 10-K.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Satement Schedules</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">No financial statement schedules are filed with this Amendment No.1 to our Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The following is a list of exhibits filed as part of this Amendment No.1 to our Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:87.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.1</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals,&#160;Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on April&#160;1, 2013, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.2</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals,&#160;Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on May&#160;27, 2016, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.3</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals,&#160;Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on April&#160;14, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.4</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924005261/tm243656d1_ex3-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals,&#160;Inc. (previously filed as Exhibit&#160;3.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> to the Registrant&#8217;s </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Statement</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> on Form&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">S-1</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, originally filed with the SEC on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">January 19</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 202</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.5</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465924005261/tm243656d1_ex3-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Correction to the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals,&#160;Inc. (previously filed as Exhibit&#160;3.5 to the Registrant&#8217;s Registration Statement on Form&#160;S-1, originally filed with the SEC on January 19, 2024, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920058082/tm2018924d1_ex3-01.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.6</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920058082/tm2018924d1_ex3-01.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on May&#160;7, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923115233/tm2330094d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to the </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on November&#160;7, 2023, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.8</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of 6% Convertible Exchangeable Preferred Stock (previously filed as Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on November&#160;5, 2004, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.9</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Series&#160;A Preferred Stock (previously filed as Exhibit&#160;3.5 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (No.&#160;333-218305), originally filed with the SEC on July&#160;17, 2017, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920138563/tm2039082d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3.10</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920138563/tm2039082d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on December&#160;22, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.1</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen of Common Stock Certificate (previously filed as Exhibit&#160;4.1 to Registrant&#8217;s Registration Statement on Form&#160;S-1, File No.&#160;333-109653, originally filed with the SEC on February&#160;17, 2004, as subsequently amended, and incorporated herein by reference).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.2</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen of Preferred Stock Certificate of Designation (previously filed as Exhibit&#160;3.2 to Registrant&#8217;s Registration Statement on Form&#160;S-1, File No.&#160;333-119585, originally filed with the SEC on October&#160;21, 2004, as subsequently amended, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.3</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant to purchase shares of Cyclacel Pharmaceuticals,&#160;Inc. Common Stock (previously filed as Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on July&#160;1, 2011, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.4</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of December&#160;14, 2012, by and between the Company and Aspire Capital Fund, LLC (previously filed as Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on December&#160;17, 2012, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.5</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated November&#160;14, 2013, by and between the Company and Aspire Capital Fund, LLC (previously filed as Exhibit&#160;4.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q, originally filed with the SEC on November&#160;14, 2013, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.6</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant to purchase shares of Cyclacel Pharmaceuticals,&#160;Inc.&#8217;s Common Stock (previously filed as Exhibit 4.3 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 333-218305), originally filed with the SEC on July 17, 2017, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/tm2016791d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.7</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/tm2016791d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (previously filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on April 24, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/tm2016791d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.8</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920051033/tm2016791d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Warrant (previously filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on April 24, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920138563/tm2039082d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.9</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465920138563/tm2039082d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (previously filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December 22, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.10</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Pre-Funded Common Stock Purchase </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant (previously filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December 2</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">6</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 202</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.11</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant (previously filed as Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December 26, 2023, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex4d12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.12*</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex4d12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities (previously filed as Exhibit&#160;4.12 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;21, 2024, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.1</span></a>&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2006 Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on May&#160;24, 2012, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.2</span></a>&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2015 Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May 22, 2015, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/tv495639_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.3</span></a>&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/tm2318711d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2018 Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form 8-K originally filed with the SEC on June 1</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 202</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.4</span></a>#</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Clinical Collaboration Agreement by and between Cyclacel Pharmaceuticals,&#160;Inc. and the University of Texas M.D. Anderson Cancer Center dated as of August&#160;21, 2018 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q for the quarterly period ended September&#160;30, 2018 and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837020013741/cycc-20200930ex1017c6286.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.5</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837020013741/cycc-20200930ex1017c6286.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Cyclacel Pharmaceuticals, Inc. 2020 Inducement Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on November&#160;12, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837020013741/cycc-20200930ex1028db6db.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.6</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837020013741/cycc-20200930ex1028db6db.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Stock Option Agreement under the Cyclacel Pharmaceuticals, Inc. 2020 Inducement Equity Incentive Plan (previously filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on November 12, 2020, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465921082608/tm2120056d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.7</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923056001/tm2314647d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis (previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">May 4</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 202</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465921082608/tm2120056d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.8</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923056001/tm2314647d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Cyclacel Pharmaceuticals, Inc. and Paul McBarron (previously filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May 4, 2023 and incorporated herein by reference).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.7pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837023019369/cycc-20221231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.9</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837023019369/cycc-20221231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement for directors (previously filed as Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K/A, originally filed with the SEC on November 29, 2023, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.10</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Placement Agency Agreement by and between Cyclacel Pharmaceuticals, Inc. and Ladenburg Thalmann &amp; Co. Inc., dated December 21, 2023 (previously filed as Exhibit 10.1 the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December 26, 2023 and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.11</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement by and between Cyclacel Pharmaceuticals, Inc. and the Purchasers, dated December 21, 2023 (previously filed as Exhibit 10.2 the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December 26, 2023 and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.12</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis and Paul McBarron, dated December 21, 2023 (previously filed as Exhibit 10.3 the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December 26, 2023 and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.13*</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement by and between Cyclacel Pharmaceuticals, Inc. and Brian Schwartz, M.D., dated January 26, 2024 (previously filed as Exhibit&#160;10.13 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;21, 2024, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">21</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Cyclacel Pharmaceuticals,&#160;Inc. (previously filed as Exhibit&#160;21 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;26, 2014, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm (previously filed as Exhibit&#160;23.1 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;21, 2024, and incorporated herein by reference)..</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cycc-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">31.1</span></a>**</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cycc-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Spiro Rombotis, pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cycc-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">31.2**</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cycc-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Paul McBarron, pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Spiro Rombotis, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (Subsections&#160;(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) (previously filed as Exhibit&#160;32.1 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;21, 2024, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Paul McBarron, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (Subsections&#160;(a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) (previously filed as Exhibit&#160;32.2 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;21, 2024, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">97.1*</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1130166/000155837024003713/cycc-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Clawback Policy (previously filed as Exhibit&#160;97.1 to the Registrant&#8217;s Annual Report on Form&#160;10-K, originally filed with the SEC on March&#160;21, 2024, and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following materials from Cyclacel Pharmaceuticals,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2022, formatted in Inline XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Balance Sheets, (iii)&#160;the Condensed Consolidated Statements of Cash Flows, and (iv)&#160;Notes&#160;to Condensed Consolidated Financial Statements.</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Exhibits:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Indicates management compensatory plan, contract or arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Confidential treatment has been granted with respect to certain portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities and Exchange Act of 1934, as amended.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Previously Filed.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Previously Furnished</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_003448ec_b14b_4bc4_b29d_472fa27c13e0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CYCLACEL PHARMACEUTICALS,&#160;INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: April 29, 2024</p></td><td style="vertical-align:bottom;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Paul McBarron</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paul McBarron</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer, Chief Financial Officer &amp; Executive Vice President, Finance</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>cycc-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/29/2024 05:11:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.3pt 0pt;"><b style="color:#231f20;font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">CERTIFICATION UNDER SECTION 302</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.44pt 0pt;"><b style="color:#231f20;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 0pt;"><font style="color:#231f20;">I, Spiro Rombotis, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this report on Form 10-K/A for the year ended December 31, 2023 of Cyclacel Pharmaceuticals, Inc.;</font></td></tr></table><div style="margin-top:0.44pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><div style="margin-top:0.44pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><div style="margin-top:0.44pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:0.44pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">a)&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">b)&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">c)&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">d)&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting: and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:0.44pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="color:#231f20;">Date: April 29, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">/s/ Spiro Rombotis</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">Spiro Rombotis</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">President &amp; Chief Executive Officer</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">(Principal Executive Officer)</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>cycc-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/29/2024 05:11:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.3pt 0pt;"><b style="color:#231f20;font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">CERTIFICATION UNDER SECTION 302</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.44pt 0pt;"><b style="color:#231f20;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="color:#231f20;">I, Paul McBarron, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this report on Form 10-K/A for the year ended December 31, 2023 of Cyclacel Pharmaceuticals, Inc.;</font></td></tr></table><div style="margin-top:0.44pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><div style="margin-top:0.2pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.2pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><div style="margin-top:0.2pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0.2pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">a)&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.2pt 0pt;"><font style="color:#231f20;">b)&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.4pt 0pt;"><font style="color:#231f20;">c)&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.4pt 0pt;"><font style="color:#231f20;">d)&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.4pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:0.4pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.4pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.4pt 0pt;"><font style="color:#231f20;">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.4pt 0pt;"><font style="color:#231f20;">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0.4pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="color:#231f20;">Date: April 29, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:10.35pt;"><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">/s/ Paul McBarron</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr style="height:10.25pt;"><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">Paul McBarron</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr style="height:10.25pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr style="height:10.25pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">Chief Operating Officer, Chief Financial Officer and Executive Vice President, Finance</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr style="height:10.25pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">(Principal Financial Officer)</font></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cycc-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/29/2024 5:12:07 PM-->
<!--Modified on: 4/29/2024 5:12:07 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:link="http://www.xbrl.org/2003/linkbase" targetNamespace="http://www.cyclacel.com/20231231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cycc="http://www.cyclacel.com/20231231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cyclacel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>cycc-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/29/2024 5:12:07 PM-->
<!--Modified on: 4/29/2024 5:12:07 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="cycc-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.cyclacel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="cycc-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.cyclacel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="us-gaap_CapitalUnitsByClassAxis_1" xlink:title="us-gaap_CapitalUnitsByClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="us-gaap_CapitalUnitClassDomain_1" xlink:title="us-gaap_CapitalUnitClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CapitalUnitsByClassAxis_1" xlink:to="us-gaap_CapitalUnitClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CapitalUnitsByClassAxis_1 To us-gaap_CapitalUnitClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cycc-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/29/2024 5:12:07 PM-->
<!--Modified on: 4/29/2024 5:12:07 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cycc-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/29/2024 5:12:07 PM-->
<!--Modified on: 4/29/2024 5:12:07 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="cycc-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:presentationLink xlink:role="http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable_638500075273663863" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638500075273663863" xlink:to="us-gaap_StatementClassOfStockAxis_638500075273663863" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638500075273663863" xlink:to="us-gaap_ClassOfStockDomain_638500075273663863" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638500075273663863" xlink:to="us-gaap_CommonStockMember_638500075273663863" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638500075273663863" xlink:to="us-gaap_PreferredStockMember_638500075273663863" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638500075273663863" xlink:to="dei_DocumentInformationLineItems_638500075273663863" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentType_638500075273663863" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentPeriodEndDate_638500075273663863" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentAnnualReport_638500075273663863" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentTransitionReport_638500075273663863" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638500075273663863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityFileNumber_638500075273663863" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityRegistrantName_638500075273673780" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityIncorporationStateCountryCode_638500075273673780" order="7" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityTaxIdentificationNumber_638500075273673780" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityAddressAddressLine1_638500075273673780" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityAddressAddressLine2_638500075273673780" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityAddressCityOrTown_638500075273673780" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityAddressStateOrProvince_638500075273673780" order="12" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityAddressPostalZipCode_638500075273673780" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_CityAreaCode_638500075273673780" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638500075273673780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_LocalPhoneNumber_638500075273673780" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638500075273683894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_Security12bTitle_638500075273683894" order="16" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638500075273683894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_TradingSymbol_638500075273683894" order="17" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638500075273683894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_SecurityExchangeName_638500075273683894" order="18" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638500075273683894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityCurrentReportingStatus_638500075273683894" order="19" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638500075273683894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityInteractiveDataCurrent_638500075273683894" order="20" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638500075273683894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityFilerCategory_638500075273683894" order="21" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638500075273693502" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntitySmallBusiness_638500075273693502" order="22" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638500075273693502" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityEmergingGrowthCompany_638500075273693502" order="23" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638500075273693502" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638500075273693502" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638500075273693502" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityShellCompany_638500075273693502" order="25" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638500075273693502" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_CurrentFiscalYearEndDate_638500075273693502" order="26" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638500075273703877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentFiscalYearFocus_638500075273703877" order="27" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638500075273703877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_DocumentFiscalPeriodFocus_638500075273703877" order="28" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638500075273703877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityCentralIndexKey_638500075273703877" order="29" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638500075273703877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_AmendmentFlag_638500075273703877" order="30" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription_638500075273703877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_AmendmentDescription_638500075273703877" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638500075273703877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityWellKnownSeasonedIssuer_638500075273703877" order="32" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638500075273713830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityVoluntaryFilers_638500075273713830" order="33" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638500075273713830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityPublicFloat_638500075273713830" order="34" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638500075273733462" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_EntityCommonStockSharesOutstanding_638500075273733462" order="35" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638500075273733462" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638500075273663863" xlink:to="dei_IcfrAuditorAttestationFlag_638500075273733462" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140081811059520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cyclacel Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1707622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Connell Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;1500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Berkeley Heights<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">517-7330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No. 1 on Form 10-K/A (this &#8220;Amendment&#8221;) amends the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 21, 2024 (the &#8220;Original 10-K&#8221;). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,622,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,318,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYCC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYCCP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=0V)&&;M^E]@>=-HO,X,%Q,Y[6B>#4-5+ONN9SJ&=7C X1BY[!\W@OE8S(T
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  Z(G5@D'INBK0   /@!   :
M          "  3L7  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    (  Z(G5AED'F2&0$  ,\#   3              "  2 8  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  &H9      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>5</ContextCount>
  <ElementCount>36</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="cycc-20231231x10ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  cycc-20231231x10ka.htm 9</Log>
  </Logs>
  <InputFiles>
    <File>cycc-20231231.xsd</File>
    <File>cycc-20231231_def.xml</File>
    <File>cycc-20231231_lab.xml</File>
    <File>cycc-20231231_pre.xml</File>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" isUsgaap="true" original="cycc-20231231x10ka.htm">cycc-20231231x10ka.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cycc-20231231x10ka.htm": {
   "nsprefix": "cycc",
   "nsuri": "http://www.cyclacel.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cycc-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cycc-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cycc-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cycc-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cycc-20231231x10ka.htm"
     ]
    }
   },
   "keyStandard": 36,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 5,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 43,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cycc-20231231x10ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cycc-20231231x10ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r7"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001558370-24-006141-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-006141-xbrl.zip
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M($ 4C@% VKTU6ED" VQZ<8?ZBM#':!$5,J&O0C0SW*LV%7)OHY9N6YM(]2"
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M\G_?RJ/+%^:3*/V5[,M_ 5!+ P04    "  .B)U8D"L2>3('  #:4P  %0
M &-Y8V,M,C R,S$R,S%?<')E+GAM;.6<75/C-A2&[W>F_\%-K_-IR-<L=$*
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M<_-5$J6='^>?@A/JA_H^Q_/_ %!+ P04    "  .B)U88K&>XQFN  #MB@@
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M/M<P^E_/CQJ6//WP]>-O]539^3CNW+*%Q_;=V%ZX^@?$>.-E4+AE>_#-;]]
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MAS/VEAEVLSQZ>3/5SO;A'M[+NG-R?+YW?-X-S;QL%8,Q:,HFF=J^>&GVOKP
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M IGG>M&%G'W@@1Q*I"E7]#>CU@"6Q(MT#:0TRP?(L:(Z) 96))]8"BNL%BV
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MQ/W]7'WV3Q[(:=X95,#^/(ZL6V#?7-^ME!^LS#/F O;G$2I/!/MRH?+Z-J*
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MBW@?FIL)W5,C[G 5!303/I:,^"K QB"^-[0= $Q'C%)K0 ;<[X_7GQE6PA>
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M(Y^)+89 R)J?Q=QTXU ,-[P=X#+RS0GB5Y)RR_.W+8ZT<^D>ITJ&HWH5[V+
M11/O 0."C3C[)A/EY&"REJZ5-/!7RVG C7EGGB-#_)QGGF>[P:,%FN"A"3(#
M7<[HO#R,$T3#_V""09Q.D)DW+D"+LX;&FA>-)[G92B<!@2,CJF+0N$#B]1DU
M6"65%0L(K<[%W,][6H12D58AIXK':QHKTAF70VP;HCT\!)S1.*F$\4&)Q2!?
MLC%AH^OU.CLWU3[JD#F"\.JR5&<@_O[#H-L;7)7L& 0-@F@J4C,X;D2FR8(
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M*JE3$M I0TD=O6D8>\8UJS8-5=?;"I.NRNJ4!G).CCA:H]M2I744Z:JTSHM
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M% -EIF\/&=I'\ -(),@4?P6'^2%C0+'UGR@(A0B.$>#E2R6H^PR0-9"%TD@
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M1[I]-HY W3SX >N)8_UD7E?:AEGDQ_W'=)PY4<ZK$F7K 003[\%MB$)%6+4
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MCFZ%B0S3N&9<)RB.8BE0*:13>!UQ'0JI"VB')$M)X:(]5S)D$11K<@#!'3%
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M(3G03&\$A/_:HS'PPX!.))\?:!P?-]I'"TQV94UK:O>JB7UWY?3_4$L#!!0
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M@;7:NO7Q/*9@#:9EXQ8_ @,P+TC?SQ7:N +"&T:-I0::PO!A$HRE@9R2WW/
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M(R@K[AP: @OUZ$3R\M#D^+C1/IKCOKW7-*:V/ZLPO],X_3]02P$"% ,4
M"  .B)U8_G-FH H$  ":$0  $0              @ $     8WEC8RTR,#(S
M,3(S,2YX<V102P$"% ,4    "  .B)U8#NNF00D/   5M   %0
M    @ $Y!   8WEC8RTR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ #HB=
M6 (\A%%;"   ,%T  !4              ( !=1,  &-Y8V,M,C R,S$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    (  Z(G5B0*Q)Y,@<  -I3   5
M  "  0,<  !C>6-C+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    "  .B)U8
M8K&>XQFN  #MB@@ %@              @ %H(P  8WEC8RTR,#(S,3(S,7@Q
M,&MA+FAT;5!+ 0(4 Q0    (  Z(G5BKTBZF0@D  ) S   8
M  "  ;71  !C>6-C+3(P,C,Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    "  .
MB)U8*1[6[7$)  !\,@  &               @ $MVP  8WEC8RTR,#(S,3(S
B,7AE>#,Q9#(N:'1M4$L%!@     '  < V $  -3D      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>cycc-20231231x10ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cycc-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_roDKPv3T-UabBA0YR-ktcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_4_26_2024_7FFeAjS8YUSrkLR0vOFgEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_NymzZFCcf0qNgu-5yAvKpw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_j20pSvIDfESVrpa1xIGz0g">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_lMIyVl6BG0q2VomkBhG4hw_1_1">0001130166</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_jv8TfxMpqESAD4jru3MGRA_2_1">true</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_bHFCYAa_JE6WBTF3_6L-Yw_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_UbZuhwxaEk6hITU-VSyyYQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Hidden_tL2oQmtRC0mZLK9vIiSoIw">Cyclacel Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_nPfhrnOirEiN-mW6kU1qeg">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_uSuEt39qlkK1dVg4NrDXZQ_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_NXeL6PNIxEaYa7EPJpw6AA">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_1GB4L4XMN0-3j0ROLoOHFw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_mNzQMMTaO0OlYD2qBrgSJA_3_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_EzI2m8XZk0WLFHL-rcqsRQ">000-50626</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_7g7lL6XWSEaM93HpA5HTAg_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_j8lW8u3e_kq-NlumLnlI2g_0_1">91-1707622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_Baj7iedXv0em3x_G8lxPkQ">200 Connell Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_FBmak3gFSkapGzKoHm9o-w">Suite&#160;1500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_lATntmXKA06o9ocOMDgcXg">Berkeley Heights</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_-sYTCU1SEkq0SKI9lMbTVA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_5geIrcVdw0u52j2ngsm1AQ_3_1">07922</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_EpcEy8l4sEKSzWQpqrFfYw">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_UpSQ-Hd4uEStbI59eOTkug">517-7330</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w"
      id="Tc_kWpNZl0800qJpt_5GLDP-w_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w"
      id="Tc_tE-uBy4NVk6wXKp7pLNZcw_2_1">CYCC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_U5kU8x00_0WdlOnhKk485w"
      id="Narr_Fa9BalgqSEKzQLu4si1Hbg">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg"
      id="Tc_zMRMruZbmUep42Z3445zyw_3_0">Preferred Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg"
      id="Tc_OFpknJF5DUS74zixGxyKkA_3_1">CYCCP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_AnbpFCdwXUWL77KytRbLMg"
      id="Narr_cTKCoXO14ECJm3YmQ_cgbw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_siifVTM6n0yGVHq2P1CHpA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_difjs6xfZkKjKA3CYeQ3zQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_wuQ2NMPgJ02cM1PPd6J3Gw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_el0jlz1cbkyB48F7ScHXhg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_mzeqbf7HDEibs9MKWMGvIA_1_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_KEZpTUDOz0mPJZ6WZR4jbw_1_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Tc_joiHdWRUtkCQOsfa1Ubkxg_2_1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_t0yZ_r-eP0W772If2r8lMQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_MhrZdgFvUESlsjZqkCn_7g">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_SxlZq6emHU-211D4DNE_Rw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_roDKPv3T-UabBA0YR-ktcA"
      decimals="0"
      id="Narr_3eWBnaqsEEKwVve-dsrOZQ"
      unitRef="Unit_Standard_USD_j20pSvIDfESVrpa1xIGz0g">5622362</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_4_26_2024_7FFeAjS8YUSrkLR0vOFgEg"
      decimals="INF"
      id="Narr_7RRB6jcjEkiIsiuH5d8dDw"
      unitRef="Unit_Standard_shares_NymzZFCcf0qNgu-5yAvKpw">1318257</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription
      contextRef="Duration_1_1_2023_To_12_31_2023_SjqMf88hOUm9UwMWgsFr1A"
      id="Narr_U2Pj4vaIikOqHXNtpblHbg">This Amendment No. 1 on Form 10-K/A (this &#x201c;Amendment&#x201d;) amends the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as originally filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 21, 2024 (the &#x201c;Original 10-K&#x201d;). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;).</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
